Bio Technology - MedGadget

Laurus Labs Galenvs acquisition graphic about oligonucleotide technology

Laurus Labs Galenvs Acquisition: The Oligonucleotide and Nanoparticle Technology Behind the Deal

The Laurus Labs Galenvs acquisition buys oligonucleotide and nanoparticle skills. What the technology involves and what is not shown.

October 30, 2026

Molecular Partners workforce reduction 2026 graphic about targeted radiotherapeutics

Bio Technology

Molecular Partners Workforce Reduction 2026: How Targeted Radiotherapeutics Work

The Molecular Partners workforce reduction 2026 refocuses a biotech on radio-DARPins. How targeted radiation drugs work and where candidates stand.

October 30, 2026

Geron IMpactMF trial discontinued graphic explaining a Phase 3 futility decision

Bio Technology

Geron IMpactMF Trial Discontinued: What a Futility Call Means in Myelofibrosis

What the Geron IMpactMF trial discontinued decision means: how monitoring committees work, what futility is and what is still unknown.

October 30, 2026

Graphic: dual-target CAR-T shown as two cells, one large and one small, with gold centres

Bio Technology

Dual-Target CAR-T Explained: What VL-2511 Could Mean for Myeloma

Dual-target CAR-T explained: how VL-2511 aims at BCMA and CD19 in multiple myeloma, why it is still experimental and what patients should know.

October 23, 2026

Graphic: AI drug discovery 2026, AstraZeneca and insitro collaboration on target discovery for MASH and cardiomyopathies

Bio Technology

AstraZeneca Signs AI Drug-Discovery Deal Worth Up to $1.5 Billion With insitro

AI drug discovery 2026: AstraZeneca and insitro target MASH and heart disease. $40M upfront, up to ~$1.46B in milestones. What the platform must prove.

October 16, 2026

Timeline graphic: Alaunos Velaris Therapeutics acquisition, from deal close in 2026 through first trial filings in 2027, proof-of-concept data in 2028 and funded runway into 2029

Bio Technology

Alaunos Acquires Velaris Therapeutics and Announces $350 Million Financing for Pulmonary Hypertension Research

Alaunos Velaris Therapeutics acquisition closes with a $350M Fairmount-led financing for pulmonary hypertension drugs. None has been tested in people.

October 14, 2026

Everest Medicines mRNA team: Lakshmi Srinivasan and Brandon Coder join, with cancer vaccine candidates EVM14 and EVM16

Bio Technology

Everest Medicines Strengthens mRNA Team with Two Former Moderna Executives

Everest Medicines mRNA team adds two former Moderna scientists to lead translational work on its cancer vaccines EVM14 and EVM16.

October 12, 2026

Graphic: Ribo RBD3133 INHBE-silencing siRNA for obesity with a DNA helix and EU Phase 1 filing label

Bio Technology

Ribo Files EU Trial Application for Obesity siRNA RBD3133

Ribo has filed an EU application for a Phase 1 trial of RBD3133, an INHBE-targeting siRNA for obesity. What the gene evidence shows and what is unknown.

October 9, 2026

Graphic: Andelyn Biosciences in the US linked through PQP to EU and UK clinical sites for gene therapy supply

Bio Technology

Andelyn Biosciences and PQP Group Partner on EU and UK Gene Therapy Supply

Andelyn Biosciences and PQP Group will coordinate EU and UK supply of US-made cell and gene therapies, from QP release to import and depot. How it works.

October 9, 2026

Bio Technology

DaltonTx Antibody Discovery Platform Launches AI Workflow

DaltonTx antibody discovery tools combine AI design, structure prediction and validation in one workflow that evaluates millions of sequences in hours.

October 2, 2026